Takeda files dengue vaccine for regulatory approval in EU

By The Science Advisory Board staff writers

March 26, 2021 -- The European Medicines Agency (EMA), an agency in the European Union (EU), has accepted Takeda Pharmaceutical's filing packages for its dengue vaccine candidate (TAK-003), which is under investigation for its ability to prevent dengue due to any dengue virus serotype in individuals ages 4-60.

Additionally, Takeda is participating in the EMA's first-ever parallel assessment of a medicinal product for use in the EU and in the EU-M4all (previously Article 58) procedure for countries outside of the EU. That means national regulators will conduct their own assessments to determine if national marketing authorizations for TAK-003 are granted. Takeda is also seeking TAK-003 approval in dengue-endemic countries not participating in the EU-M4all procedure.

The firm plans to submit regulatory filings in Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka, and Thailand later this year. Submissions include long-term safety and efficacy data through 36 months from the ongoing phase III Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial. Takeda said it plans to present and publish data regarding that trial sometime this year.

Evotec, Takeda partner on RNA-targeting drug discovery, development
Evotec has entered into an alliance with Takeda Pharmaceutical with the goal of discovering and developing RNA-targeting small-molecule therapeutics for...
Takeda, IDT help manufacture Janssen COVID-19 vaccine
Takeda and IDT Biologika announced they will support the manufacturing of the Johnson & Johnson COVID-19 vaccine.
Takeda to acquire Maverick Therapeutics
Takeda Pharmaceutical has exercised its option to purchase T cell-targeted immunotherapy developer Maverick Therapeutics for up to $525 million in...
Startup Ensoma launches with gene therapy vector platform
A new genomic medicine startup called Ensoma made its corporate debut this week, raising $70 million in financing and entering into a strategic collaboration...
Evozyne to develop synthetic proteins for Takeda gene therapies
Molecular engineering company Evozyne has signed a strategic collaboration and license agreement with Takeda Pharmaceutical. The partnership's aim is...

Copyright © 2021 scienceboard.net

HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter